{"product_id":"passagebio-business-model-canvas","title":"Passage Bio Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas for a Gene Therapy Biotech: Strategy, Partners, Revenue Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Passage Bio’s business model in a concise, actionable Business Model Canvas that maps value propositions, key partners, revenue streams, and growth levers. Perfect for investors, advisors, and founders seeking competitive insight and execution-ready analysis. Purchase the complete, editable canvas to benchmark strategy and accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic research alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with universities and medical schools fuel target discovery and translational science for rare CNS disorders, supplying disease models, biomarkers and natural history datasets that accelerate candidate selection. Co-development agreements can de-risk early biology and share up to 40% of preclinical costs. Joint publications bolster scientific credibility and strengthen regulatory dossiers for IND filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVector CDMOs \u0026amp; GMP manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialized AAV CDMOs provide scalable, GMP-compliant vector production with process development, analytics and release testing under GMP; as of 2024 these partners increasingly support technology transfer across sites to ensure reproducible quality. Flexible capacity reservations allow matching batch sizes to orphan-disease demand and mitigate supply risk for low-volume programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs \u0026amp; clinical trial networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCROs and clinical trial networks manage multi-center trials, logistics, and data integrity for Passage Bio, coordinating complex site operations and regulatory compliance across regions. Rare disease networks accelerate patient identification and enrollment in a space of 7,000+ rare diseases affecting ~300 million people worldwide, improving recruitment velocity. Centralized imaging, PK\/PD, and biomarker labs standardize endpoints and data harmonization. These partnerships compress timelines and enhance trial quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy organizations support patient finding, education, and trial awareness, with over 7,000 rare disease groups globally (Global Genes, 2024). They inform meaningful endpoint selection and burden-of-disease insights, co-create materials that improve adherence and informed consent, and their registries supply longitudinal outcomes data used by regulators and payers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient identification \u0026amp; recruitment\u003c\/li\u003e\n\u003cli\u003eEndpoint \u0026amp; burden insights\u003c\/li\u003e\n\u003cli\u003eCo-created adherence\/consent materials\u003c\/li\u003e\n\u003cli\u003eRegistries for longitudinal regulatory\/payer evidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP licensors \u0026amp; capsid technology providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess to novel AAV capsids, promoters and delivery enhancers expands CNS tropism and payload efficiency; by 2024 over 1,000 engineered capsid variants had been reported, boosting transduction and reducing peripheral exposure. Licensing secures freedom to operate and accelerates platform evolution; option structures align cash outlays with milestones (IND, POC, BLA) and de‑risk spend. Cross‑licenses enable combination strategies and new indications, unlocking collaboration value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapsid breadth: \u0026gt;1,000 engineered variants (2024)\u003c\/li\u003e\n\u003cli\u003eMilestone alignment: upfronts minimized via options\u003c\/li\u003e\n\u003cli\u003eFreedom to operate: licenses reduce IP litigation risk\u003c\/li\u003e\n\u003cli\u003eCross‑license: opens combos and indication expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration cuts preclinical costs 40% and scales CNS gene therapy with 1,000+ capsids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with academia, CDMOs, CROs and patient groups accelerate CNS gene therapy, sharing up to 40% of preclinical costs and leveraging \u0026gt;1,000 engineered capsids (2024). Rare-disease networks (7,000+ groups) and registries cover ~300 million affected worldwide, speeding recruitment and regulatory evidence generation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003eModels, biomarkers\u003c\/td\u003e\n\u003ctd\u003eIND-strengthening\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003eGMP AAV production\u003c\/td\u003e\n\u003ctd\u003eTech transfer trend (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eTrials \u0026amp; data\u003c\/td\u003e\n\u003ctd\u003eFaster enrollment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003eRecruitment, registries\u003c\/td\u003e\n\u003ctd\u003e7,000+ groups; 300M people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensors\u003c\/td\u003e\n\u003ctd\u003eCapsids\/IP\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,000 variants (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Passage Bio aligning its gene‑therapy R\u0026amp;D, clinical development and commercialization strategy across the 9 BMC blocks; covers customer segments, value propositions, key partnerships, channels, revenue and funding paths, plus competitive advantages and risks—suitable for investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Passage Bio’s business model with editable cells, clarifying how its gene-therapy pipeline, R\u0026amp;D partnerships, and commercialization\/reimbursement strategies address rare-disease treatment gaps and investor decision points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAAV capsid \u0026amp; construct engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesigning AAV capsids and constructs for CNS targeting, cell specificity, and expression control is core to Passage Bio’s R\u0026amp;D, with promoter selection and codon optimization used to tune therapeutic windows. In vitro and in vivo screens refine potency and safety, supporting iterative design cycles that lower immunogenicity and off-target risks. By 2024 there were two FDA-approved AAV therapies, underscoring clinical translation potential and rigorous safety benchmarking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreclinical pharmacology \u0026amp; toxicology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRobust preclinical studies establish dose, biodistribution and toxicology in relevant models, typically including rodent and non-rodent species as per FDA guidance. Biomarker development connects molecular correction to functional outcomes using validated PD and surrogate markers. GLP toxicology packages are assembled to support IND submissions. Translational plans map animal NOAEL and exposure data to first-in-human dosing via allometric and PK\/PD modeling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing \u0026amp; CMC scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcess development improves AAV yield, purity and batch-to-batch consistency to meet clinical and commercial demands, reducing downstream costs and time to release. Robust release assays validate identity, potency and safety, enabling confident lot release for trials. Comparability protocols de-risk manufacturing changes across scales while comprehensive CMC documentation underpins regulatory approvals and lifecycle management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development \u0026amp; regulatory\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDesigning adaptive early-phase trials accelerates proof-of-concept and dose finding; Passage Bio leverages orphan, RMAT and Breakthrough pathways where eligible (pathways active in 2024). Continuous regulator engagement aligns endpoints and CMC plans, while independent data monitoring and pharmacovigilance ensure patient safety throughout development.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdaptive early-phase trials\u003c\/li\u003e\n\u003cli\u003eOrphan\/RMAT\/Breakthrough pursuit (2024 active)\u003c\/li\u003e\n\u003cli\u003eRegulator alignment on endpoints \u0026amp; manufacturing\u003c\/li\u003e\n\u003cli\u003eOngoing DMC \u0026amp; pharmacovigilance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access \u0026amp; medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHealth economic models quantify lifetime value and QALYs to justify one-time therapy pricing, citing precedents like Zolgensma at $2.125M and Luxturna at $850,000; outcomes-based agreements with payers (pay-for-performance, annuity) mitigate budget impact; KOL education and peer-reviewed publications build adoption readiness; patient support programs handle navigation and long-term follow-up.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHE Models: QALYs, WTP $100k–$150k\u003c\/li\u003e\n\u003cli\u003ePricing refs: Zolgensma $2.125M; Luxturna $850k\u003c\/li\u003e\n\u003cli\u003eContracts: outcomes-based, annuity\u003c\/li\u003e\n\u003cli\u003eSupport: navigation, long-term monitoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS AAV: capsid\/promoter tuning, GLP-to-IND and CMC scale-up enable clinical translation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesigning CNS‑targeted AAV capsids\/constructs with promoter tuning and iterative in vitro\/in vivo screening drives potency and safety; by 2024 two FDA AAV approvals validated clinical translation. Rigorous GLP preclinical packages and PK\/PD modeling inform IND and first‑in‑human dosing. CMC scale‑up and release assays secure clinical supply. Adaptive trials, orphan\/RMAT pathways and HE models support pricing and payer arrangements.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e2 FDA AAV approvals (by 2024)\u003c\/td\u003e\n\u003ctd\u003eClinical translation validated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eGLP tox standard\u003c\/td\u003e\n\u003ctd\u003eIN D support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMC\u003c\/td\u003e\n\u003ctd\u003eScale‑up to clinical batches\u003c\/td\u003e\n\u003ctd\u003eComparability required\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHE\/Pricing\u003c\/td\u003e\n\u003ctd\u003eZolgensma $2.125M; Luxturna $850k\u003c\/td\u003e\n\u003ctd\u003eOutcomes\/annuity deals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Passage Bio Business Model Canvas, not a mockup—what you see is a direct extract from the final deliverable. After purchase you'll receive this exact file with all sections included. It arrives fully formatted and editable, ready for immediate use in Word and Excel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAAV platform \u0026amp; CNS know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProprietary AAV vector designs and CNS delivery expertise enable targeted gene transfer; as of 2024 Passage Bio is NASDAQ-listed (PASG) and leverages deep neuroanatomy knowledge to tailor routes of administration. Internal in vitro and in vivo assays de-risk human translation, while a reusable AAV platform accelerates pipeline development across multiple neurologic indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual property portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s intellectual property portfolio spans patents on vectors, promoters, methods, and manufacturing to lock core modality rights. Trade secrets safeguard process yields and analytics critical for consistent commercial manufacturing. 2024 freedom-to-operate analyses steer indication selection toward clearer patent landscapes and lower litigation risk. Defensive filings are used to preserve long-term exclusivity and strengthen partnering leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing capability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAccess to dedicated GMP suites, validated processes, and QC assays underpins supply reliability for Passage Bio, ensuring consistent batch-to-batch quality. In-house capacity plus partnered manufacturing supports clinical programs and early commercial launches. Robust release testing and stability programs maintain regulatory compliance. Tight supply-chain controls reduce raw-material and vendor risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and real-world datasets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePreclinical, trial, and registry data together build robust efficacy and safety narratives that drive regulatory review and commercial planning.\u003c\/p\u003e\n\u003cp\u003eNatural history datasets contextualize treatment impact versus disease course, improving benefit-risk assessment in 2024 submissions.\u003c\/p\u003e\n\u003cp\u003eDigital biomarkers and imaging increase outcome sensitivity, and post-market evidence underpins label expansion and payer renewals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData sources: preclinical, trials, registries\u003c\/li\u003e\n\u003cli\u003eNatural history: comparator context for rare diseases\u003c\/li\u003e\n\u003cli\u003eDigital biomarkers: enhanced sensitivity\u003c\/li\u003e\n\u003cli\u003ePost-market: supports label and reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExperienced scientific \u0026amp; regulatory team\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExperienced leaders with gene therapy, neurology and CMC track records drive program execution; regulatory experts target accelerated pathways such as RMAT and FDA priority review (6‑month target) while clinical ops optimize rare‑disease site performance and BD\/market access teams pursue partnerships and reimbursement channels.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMAT designation accelerates development\u003c\/li\u003e\n\u003cli\u003eFDA priority review: 6 months\u003c\/li\u003e\n\u003cli\u003eOrphan drug US exclusivity: 7 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary AAV platform and CNS delivery expertise accelerate multi-indication development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProprietary AAV platform and CNS delivery expertise (PASG on NASDAQ) accelerate multi‑indication development and reduce clinical translation risk.\u003c\/p\u003e\n\u003cp\u003ePatents, trade secrets, and 2024 freedom‑to‑operate analyses protect modality rights and guide indication selection.\u003c\/p\u003e\n\u003cp\u003eGMP suites, validated QC, preclinical\/clinical\/natural‑history datasets and digital biomarkers underpin filings and commercialization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eStatus\/Metric\u003c\/th\u003e\n\u003cth\u003e2024 note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV platform\u003c\/td\u003e\n\u003ctd\u003eReusable\u003c\/td\u003e\n\u003ctd\u003ePipeline acceleration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003ePatents \u0026amp; trade secrets\u003c\/td\u003e\n\u003ctd\u003eFTO analyses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eGMP suites\u003c\/td\u003e\n\u003ctd\u003eClinical\/commercial ready\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData\u003c\/td\u003e\n\u003ctd\u003eNatural history \u0026amp; biomarkers\u003c\/td\u003e\n\u003ctd\u003eRegulatory support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne-time, disease-modifying therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOne-time, disease-modifying delivery can correct underlying genetic deficits with a single administration—commercial precedent includes Zolgensma priced at about 2.125 million USD—reducing chronic treatment burden and adherence challenges tied to lifelong regimens that often cost hundreds of thousands annually. Clinical programs have shown durable functional gains beyond 2 years in multiple in vivo studies, offering compelling value versus ongoing symptomatic care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS-targeted precision delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEngineered AAVs and CNS routes target neuron and glia specificity to boost on-target efficacy while reducing systemic exposure; this enables therapy for high-unmet-need CNS disorders such as Parkinson’s (≈10 million people worldwide) and dementia (~55 million), supporting differentiated safety and benefit profiles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccelerated development in rare diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrphan-focused strategy leverages US orphan drug exclusivity of 7 years and expedited pathways (priority review target 6 months) to shorten timelines. Biomarker-rich, often sub-50 patient trials accelerate signal detection and de‑risk go\/no-go decisions. Patient-centric endpoints capture functional benefit valued by regulators and payers, enabling faster availability for underserved populations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive patient support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eComprehensive patient support combines navigation, genetic testing access and travel assistance to lower barriers to therapy initiation, while long-term monitoring programs track safety and outcomes over time; educational resources in 2024 support families and clinicians across a rare-disease population of ~300 million worldwide, strengthening holistic care that improves real-world effectiveness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNavigation: centralized case management\u003c\/li\u003e\n\u003cli\u003eTesting: facilitated genetic access\u003c\/li\u003e\n\u003cli\u003eTravel: logistical assistance\u003c\/li\u003e\n\u003cli\u003eMonitoring: long-term outcomes tracking\u003c\/li\u003e\n\u003cli\u003eEducation: family and clinician empowerment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth-economic value creation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHealth-economic value can offset lifelong medical costs often exceeding $1M for rare genetic disorders, reducing caregiver burden via single-dose interventions.\u003c\/p\u003e\n\u003cp\u003eOutcomes-based contracts align price with performance and are increasingly adopted for gene therapies, tying payments to measured clinical endpoints.\u003c\/p\u003e\n\u003cp\u003eReal-world evidence through 3–5 year follow-ups (2024) supports durability claims, and predictable single-dose dosing simplifies resource planning for treatment centers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOffset: lifetime costs \u0026gt;$1M\u003c\/li\u003e\n\u003cli\u003eContracts: outcomes-tied pricing\u003c\/li\u003e\n\u003cli\u003eDurability: 3–5 year RWE (2024)\u003c\/li\u003e\n\u003cli\u003eDosing: single-dose, predictable logistics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne-time AAV CNS therapies: durable disease-modifying care that cuts lifetime rare-disease costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOne-time, disease‑modifying AAV CNS therapies offer durable benefit vs lifelong care (Zolgensma precedent US$2.125M) and can cut lifetime rare‑disease costs often \u0026gt;US$1M. Engineered AAVs enable neuron\/glia targeting for high‑unmet CNS markets (Parkinson’s ≈10M; dementia ≈55M). Orphan exclusivity (7 years) + expedited pathways and 3–5yr RWE (2024) de‑risk commercialization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZolgensma price\u003c\/td\u003e\n\u003ctd\u003eUS$2.125M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease population\u003c\/td\u003e\n\u003ctd\u003e≈300M worldwide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eParkinson’s prevalence\u003c\/td\u003e\n\u003ctd\u003e≈10M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDementia prevalence\u003c\/td\u003e\n\u003ctd\u003e≈55M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan exclusivity (US)\u003c\/td\u003e\n\u003ctd\u003e7 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE follow‑up\u003c\/td\u003e\n\u003ctd\u003e3–5 years (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKOL engagement \u0026amp; advisory boards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegular quarterly forums with dozens of KOLs solicit input on trial design, endpoints and care pathways to align programs with clinical need; Passage Bio is a NASDAQ-listed company (PASG) as of 2024. Early adopters and advisory boards champion education and guideline adoption to accelerate uptake. Transparent data sharing builds trust with clinicians and payers, while advisory insights refine launch strategy and lifecycle planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated medical science liaisons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated medical science liaisons provide balanced, scientific dialogue with specialists, translating trial data into clinical context; they support interpretation of biomarkers and imaging (eg, MRI, CSF markers) critical to gene therapy assessment. Field insights from MSLs shape evidence-generation priorities and trial design. Ongoing MSL engagement sustains therapy literacy and uptake at treatment centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient access \u0026amp; support services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCase managers coordinate testing, insurance authorization and logistics for clinical and commercial access, streamlining patient journeys. Multilingual resources reach global rare-disease populations — over 300 million people worldwide. Structured follow-up programs support adherence to monitoring and treatment schedules. Continuous feedback loops capture outcomes and patient experience to refine services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCenter of excellence partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCenter of excellence partnerships build long-term ties with high-volume neurology centers to ensure consistent patient selection and treatment delivery. Training and proctoring programs optimize administration quality and reduce procedural variability. Data-sharing agreements enable robust outcomes tracking and real-world evidence generation. Joint process mapping streamlines patient flow from referral to follow-up.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term ties: consistency in patient care\u003c\/li\u003e\n\u003cli\u003eTraining\/proctoring: improved administration quality\u003c\/li\u003e\n\u003cli\u003eData-sharing: outcomes tracking and RWE\u003c\/li\u003e\n\u003cli\u003eProcess mapping: streamlined patient flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and HTA collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly health-economics dialogues with payers and HTAs align evidence needs for Passage Bio gene therapies, enabling outcomes-based and milestone payments that reduce payer and developer risk. Integrated real-world data portals support renewals and periodic HTA reviews, while clear, harmonized contracting language facilitates cross-border access and faster patient uptake.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly HE dialogues\u003c\/li\u003e\n\u003cli\u003eOutcomes\/milestone payments\u003c\/li\u003e\n\u003cli\u003eRWD portals for renewals\u003c\/li\u003e\n\u003cli\u003eHarmonized contracting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuarterly KOL forums and MSLs drive \u0026gt;90% COE site readiness for 2024 launch; early payer talks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuarterly KOL forums and MSLs drive clinician trust and guideline adoption, aiding PASG (NASDAQ) 2024 launch plans. Case managers and COEs streamline access; \u0026gt;90% site readiness in partnered centers supports consistent delivery. Early payer talks enable outcomes-based contracts to mitigate reimbursement risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner COEs\u003c\/td\u003e\n\u003ctd\u003e~25 centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite readiness\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSL visits\/yr\u003c\/td\u003e\n\u003ctd\u003e~300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty neurology centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTherapies are delivered through high-capability hospitals and clinics experienced in CNS gene therapy, with centralized hubs coordinating patient evaluation, administration, and longitudinal follow-up; site enablement programs certify readiness and optimize throughput. With ~7,000 rare diseases worldwide and the US orphan threshold of \u0026lt;200,000 patients, concentrated channels match sparse patient geographies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-HCP scientific communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePeer-reviewed publications, symposia, and webinars educate clinicians; digital repositories host protocols and safety data and congress presentations (eg ASGCT, AAN) update on data milestones; targeted outreach focuses on geneticists and neurologists to drive trial referrals and adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatient advocacy networks raise awareness and drive trial participation by mobilizing communities; WHO estimates 300 million people live with rare diseases globally (2024). Educational toolkits demystify gene therapy basics for patients and HCPs. Registry links facilitate screening and referrals. Two-way communication captures unmet needs and informs protocol design.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital platforms \u0026amp; portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProvider and patient portals coordinate referrals, schedule management and secure messaging while supporting care continuity; telehealth handles pre- and post-procedure visits, accounting for about 10% of outpatient interactions in 2024. Content hubs deliver training, FAQs and consent materials; analytics track engagement and outcomes to refine outreach and reduce no-shows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePortals: referral + scheduling\u003c\/li\u003e\n\u003cli\u003eTelehealth: 10% of visits (2024)\u003c\/li\u003e\n\u003cli\u003eContent hubs: training \u0026amp; FAQs\u003c\/li\u003e\n\u003cli\u003eAnalytics: engagement → service improvement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnerships \u0026amp; licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn 2024 Passage Bio expanded strategic partnerships and licensing to extend reach into new regions and indications, using co-promote agreements to leverage partners’ existing commercial infrastructures while distributors managed market-specific logistics; shared investments with collaborators lowered launch risk and capital exposure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAlliances: regional and indication expansion (2024 focus)\u003c\/li\u003e\n\u003cli\u003eCo-promote: leverages partner infrastructure\u003c\/li\u003e\n\u003cli\u003eDistributors: handle local logistics\/compliance\u003c\/li\u003e\n\u003cli\u003eShared investments: reduce launch risk and capital burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHub hospitals speed rare therapy access; telehealth \u003cstrong\u003e10%\u003c\/strong\u003e regional co-promote\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTherapies via specialized hospitals with centralized hubs for evaluation and follow-up; site enablement accelerates readiness. Outreach uses journals, ASGCT\/AAN, registries and patient groups to drive referrals; telehealth ~10% of visits (2024). 2024 alliances\/co-promote expanded regional reach, lowering launch capital.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare diseases\u003c\/td\u003e\n\u003ctd\u003e~7,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS orphan threshold\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;200,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal rare patients (WHO 2024)\u003c\/td\u003e\n\u003ctd\u003e300,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth share (2024)\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 focus\u003c\/td\u003e\n\u003ctd\u003eRegional alliances \/ co-promote\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with rare CNS genetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividuals with monogenic neurodegenerative or developmental CNS disorders—often pediatric or young adult with rapid progression—represent a small but urgent segment; rare diseases affect ~300 million people worldwide (WHO) and ~50% of patients are children, while only ~5% of rare conditions have approved therapies (EURORDIS), driving high willingness to consider transformative gene-based options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCaregivers and families\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCaregivers and families, who often deliver 20–25 hours\/week of care, act as primary decision influencers managing logistics for gene therapies; as of 2024 about 30 million Americans live with rare diseases (NIH). They demand clear data on risks, benefits and lifelong monitoring, value wraparound support and financial navigation to offset high care coordination costs, and actively advocate for access and continuity of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurologists \u0026amp; genetic specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeurologists and genetic specialists are primary prescribers and referral sources for CNS gene therapies, guiding patient selection and center referrals; rare diseases affect about 300 million people worldwide (WHO). They demand robust evidence, standardized protocols and long‑term safety data — critical given landmark approvals such as Luxturna (2017) and Zolgensma (2019). Their endorsement drives center adoption and standard‑of‑care evolution. Engagement focuses on KOL networks, investigator education and consensus guideline development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers \u0026amp; health authorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers and health authorities (insurers, HTAs, government funders) finance high-cost therapies and demand clear clinical and economic value, often against HTA thresholds commonly around €20–50k per QALY in Europe; US payers focus on budget impact as health spending is roughly 18% of GDP. They increasingly prefer outcomes-linked payment models and shape access criteria and utilization management.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eInsurers \u0026amp; government funders\u003c\/li\u003e\n\u003cli\u003eDemand clinical + economic value\u003c\/li\u003e\n\u003cli\u003eOutcomes-linked payments preferred\u003c\/li\u003e\n\u003cli\u003eShape access criteria \u0026amp; utilization\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch collaborators \u0026amp; partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResearch collaborators include academic labs, consortia, and biopharma co-developers supplying assets, disease models, and trial infrastructure to accelerate Passage Bio programs. They seek platform synergies and shared IP value to enable pipeline expansion and distribute technical and financial risk. In 2024 the global gene therapy market was about 8.3 billion USD with a ~33% projected CAGR to 2030, highlighting partnership leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcademic labs: translational models, biomarker data\u003c\/li\u003e\n\u003cli\u003eBiopharma co-developers: co-funding, shared IP, CRO access\u003c\/li\u003e\n\u003cli\u003eConsortia: trial networks, site infrastructure, risk-sharing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMonogenic CNS: \u003cstrong\u003e300M\u003c\/strong\u003e, caregiver burden, \u003cstrong\u003e$8.3B\u003c\/strong\u003e market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients with monogenic CNS disorders (~300M people globally; ~30M US rare disease patients in 2024; ~50% pediatric) are high-need, high-willingness targets. Caregivers (20–25 hrs\/week) drive decisions and need care\/navigation support. Neurologists\/geneticists and HTA\/payers demand robust long-term evidence and outcomes-linked pricing; 2024 gene therapy market ≈ $8.3B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey data 2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e300M global; 30M US; 50% pediatric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCaregivers\u003c\/td\u003e\n\u003ctd\u003e20–25 hrs\/week\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket\u003c\/td\u003e\n\u003ctd\u003e$8.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and platform innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing investment in vector engineering, assay development and biomarker analytics drives Passage Bio’s discovery, preclinical studies and translational analytics, supporting pipeline breadth and differentiation. These activities create high fixed costs with a steep learning curve, typical for clinical-stage gene therapy where platform R\u0026amp;D commonly exceeds $100 million annually. Persistent platform spend unlocks cumulative knowledge and lowers marginal costs per program over time. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing \u0026amp; quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcess development, batch production and release testing for Passage Bio’s GMP AAV programs drive high per-batch costs—industry median ~$2M per AAV batch in 2023—plus facility access, raw materials and dedicated QC\/QA headcount (often tens of FTEs). Validation and stability programs typically add 10–20% overhead to manufacturing budgets. Redundant suppliers and capacity reduce risk of supply interruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trials \u0026amp; operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical trials \u0026amp; operations drive major costs for Passage Bio: site fees, CRO services, imaging and lab analyses commonly consume 40–60% of trial budgets in 2024, with specialized imaging and assays especially costly. Patient support and logistics for rare populations can exceed $50,000 per patient in 2024 due to travel, housing and concierge services. Data management, monitoring for regulatory compliance, and safety oversight including DSMB activities add substantial recurring costs and vendor fees.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory \u0026amp; compliance costs at Passage Bio cover preparation of IND\/BLA\/MAA dossiers and agency meetings, ongoing pharmacovigilance and post-approval commitments, GxP training and audits across CMO\/CDMO partners, and labeling and CMC lifecycle maintenance; FY2024 FDA BLA user fee ~ $3.24M illustrates filing cost scale.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIND\/BLA\/MAA preparation \u0026amp; meetings: major one-time fees\u003c\/li\u003e\n\u003cli\u003ePharmacovigilance\/post-approval: recurring safety surveillance budgets\u003c\/li\u003e\n\u003cli\u003eGxP audits\/training: partner compliance spend\u003c\/li\u003e\n\u003cli\u003eLabeling\/CMC lifecycle: long-term maintenance costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial \u0026amp; access infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercial and access infrastructure costs at Passage Bio in 2024 concentrate on medical affairs, market access and payer engagement, center enablement and patient services, plus RWE generation and analytics; corporate G\u0026amp;A and IP legal expenses continue to be steady drivers of operating expense.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003emedical_affairs\u003c\/li\u003e\n\u003cli\u003emarket_access_payer_engagement\u003c\/li\u003e\n\u003cli\u003ecenter_enablement_training_patient_services\u003c\/li\u003e\n\u003cli\u003ereal_world_evidence_analytics\u003c\/li\u003e\n\u003cli\u003ecorporate_G\u0026amp;A_IP_legal\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh fixed platform costs and steep AAV, clinical, and regulatory expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePlatform R\u0026amp;D drives high fixed costs (platform spend \u0026gt;$100M\/year). GMP AAV batches run ~ $2M each (industry median 2023); validation adds 10–20% overhead. Clinical ops consume 40–60% of trial budgets (2024); patient support often \u0026gt; $50,000\/patient (2024). Regulatory filing fees (FDA BLA FY2024) ≈ $3.24M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\u0026gt; $100M \/ yr (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV batch cost\u003c\/td\u003e\n\u003ctd\u003e~ $2M \/ batch (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical ops\u003c\/td\u003e\n\u003ctd\u003e40–60% of trial budget (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient support\u003c\/td\u003e\n\u003ctd\u003e\u0026gt; $50,000 per patient (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA BLA fee\u003c\/td\u003e\n\u003ctd\u003e$3.24M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne-time therapy product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of 2024 Passage Bio had no marketed products; projected primary revenue would derive from future approved AAV gene therapies. Industry per-treatment pricing (eg Zolgensma ≈ $2.1M, Luxturna ≈ $425k) reflects high value and durability. Therapies are administered at specialty centers with bundled service models and increasingly include outcomes-based payment adjustments with payers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestones from partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMilestone payments from partnerships include upfronts (commonly $5–100M) and development and regulatory milestones that can push total deal value into the high hundreds of millions or beyond. Co-development deals allow risk sharing across programs and partners, lowering Passage Bio’s solo capital needs. Commercial milestones and tiered sales-based payments activate at launch and scale, often alongside royalties. These payments provide non-dilutive funding to sustain R\u0026amp;D and advance pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing of IP and platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio can out-license vectors, promoters, or delivery methods to peers, capturing upfront fees and milestone payments while the global gene therapy market was estimated at about $7.8 billion in 2024. Royalties on partnered products create recurring revenue streams. Field-limited rights protect core programs while cross-licenses unlock new indications and collaborative R\u0026amp;D.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrants and non-dilutive funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGrants and non-dilutive funding from foundations and government initiatives in 2024 supported Passage Bio's high-unmet-need programs and enabling technologies, de-risking early research while allowing the company to retain IP rights and upside. Such funding enhances credibility and visibility with investors and partners, accelerating translational milestones without equity dilution.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: rare CNS and monogenic disorders\u003c\/li\u003e\n\u003cli\u003eBenefit: retains rights, lowers cash burn\u003c\/li\u003e\n\u003cli\u003eImpact: boosts visibility with funders and KOLs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePriority review voucher monetization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuccessful approvals in rare pediatrics may earn priority review vouchers (PRVs). Vouchers can be sold to generate immediate cash; past market transactions have fetched up to several hundred million dollars. Alternatively, using a PRV can accelerate FDA review for a higher‑value program, shortening time to market. Monetization strengthens Passage Bio’s balance‑sheet flexibility for operations, partnerships, or reinvestment as of 2024 PRVs remain transferable.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eRevenue: immediate cash from PRV sale\u003c\/li\u003e\n\u003cli\u003eStrategic: accelerate filings to increase NPV\u003c\/li\u003e\n\u003cli\u003eFinancial: enhances liquidity and balance‑sheet optionality\u003c\/li\u003e\n\u003cli\u003eMarket fact 2024: PRVs remain tradable and valuable\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-value gene therapy: $2.1M pricing, $5-100M upfronts, royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s revenue model centers on future AAV product sales (benchmarked by Zolgensma ≈ $2.1M, Luxturna ≈ $425k) plus outcomes‑linked commercial arrangements. Partner upfronts commonly range $5–100M with total deal values often reaching high hundreds of millions; royalties and out‑licenses tap a gene therapy market ~ $7.8B in 2024. Grants, PRVs (saleable for up to several hundred million) and milestone payments provide non‑dilutive cash and optionality.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRevenue stream\u003c\/th\u003e\n\u003cth\u003e2024 data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003eZolgensma $2.1M; Luxturna $425k\u003c\/td\u003e\n\u003ctd\u003eHigh per‑patient revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnerships\u003c\/td\u003e\n\u003ctd\u003eUpfronts $5–100M; deals → high hundreds M\u003c\/td\u003e\n\u003ctd\u003eNon‑dilutive R\u0026amp;D funding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\/out‑license\u003c\/td\u003e\n\u003ctd\u003eMarket ≈ $7.8B (2024)\u003c\/td\u003e\n\u003ctd\u003eRecurring revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrants \u0026amp; PRVs\u003c\/td\u003e\n\u003ctd\u003ePRVs sell for up to several hundred M\u003c\/td\u003e\n\u003ctd\u003eLiquidity and optionality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098293997916,"sku":"passagebio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/passagebio-business-model-canvas.png?v=1781803069","url":"https:\/\/pestel-analysis.com\/products\/passagebio-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}